Communiqués Lotus Pharmaceutical Co., Ltd.

Actions

1795

TW0001795003

Cours en clôture Taiwan S.E. Autres places de cotation 00:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
284 ^TWD	+2,90 %		+1,43 %	+4,41 %

11/05	Lotus Pharmaceutical Co. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
26/03	Lotus Pharmaceutical Co. annonce un changement de représentant du directeur institutionnel de la société	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Lotus Reported Unaudited December Consolidated Revenues of NT$1,372 million, showcasing MoM and YoY Growth 2023 Unaudited Consolidated Revenues Grew 16% to NT$16,958 million, marking 5th consecutive year of double-digit growth	11/01	AQ
Lotus Pharmaceutical Co., Ltd. Reports Solid Financial Results for September 2023 and Year-to-Date Growth	12/10/23	AQ
Corium and Lotus Pharmaceutical Enter into Exclusive License Agreement for Innovative Alzheimer's Disease Treatment ADLARITY® in Multiple Markets Across Asia	10/08/23	BU
LOTUS PHARMACEUTICAL AND AMARIN CORPORATION PLC ANNOUNCE EXCLUSIVE PARTNERSHIP AGREEMENT TO COMMERCIALIZE VAZKEPA IN SOUTHEAST ASIA AND SOUTH KOREA	02/08/23	AQ
PharmaMar receives approval of Zepzelca for the treatment of metastatic small cell lung cancer in Taiwan	12/07/23	AQ
NRx Pharmaceuticals, Lotus Pharmaceuticals et Alvogen Inc. annoncent leur collaboration pour le développement et la commercialisation du NRX-101	07/06/23	GL
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101	05/06/23	GL
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101	05/06/23	AQ
Lotus Announces Exclusive License and Development Agreement with Unicycive for Renazorb in Korea	07/02/23	AQ
Lotus partners with Eurofarma & Adalvo, launching Nuvyor (Lenalidomide) in Brazil, indicated in the treatment of multiple myeloma	02/02/23	AQ
Lotus Obtains Tentative Approval for Nintedanib ANDA from the US FDA	16/01/23	AQ
LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY	11/11/22	PR
Mithra and Lotus announce approval of ALYSSA, an innovative oral contraceptive, in both Taiwan and Hong Kong	21/09/22	AQ
Lotus Launches Lenalidomide Capsules 5mg, 10mg, 15mg, and 25mg, Generic Version of Revlimid in the US	05/09/22	AQ
Lotus Receives Tentative Approval for Midostaurin ANDA from the US FDA	26/08/22	AQ
Lotus Crowned as One of Asia's Best Employers of the Year 2022	22/08/22	AQ
Lotus Pharmaceutical : Clarification of Media Report	17/08/22	PU
Lotus Pharmaceutical : will attend the investor conference held by Yuanta Securities	12/08/22	PU
Lotus Pharmaceutical : will attend the investor conference held by Fubon Securities	12/08/22	PU
Lotus Pharmaceutical : will attend the online investor conference held by Cathay Securities	12/08/22	PU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Lotus Pharmaceutical Co., Ltd.

Actions

1795

TW0001795003

Communiqués

Filtres